Kineta Price to Sales Ratio 2014-2024 | KANT
Historical PS ratio values for Kineta (KANT) over the last 10 years. The current P/S ratio for Kineta as of September 19, 2024 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Kineta P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
| 2024-09-18 |
0.57 |
|
inf |
| 2024-06-30 |
0.53 |
0 |
0.00 |
| 2024-03-31 |
0.53 |
$0.52 |
1.01 |
| 2023-12-31 |
3.63 |
$0.55 |
6.57 |
| 2023-09-30 |
3.40 |
$0.65 |
5.22 |
| 2023-06-30 |
2.58 |
$0.69 |
3.72 |
| 2023-03-31 |
3.31 |
$0.35 |
9.54 |
| 2022-12-31 |
6.35 |
$0.41 |
15.63 |
| 2022-09-30 |
1.57 |
$0.72 |
2.17 |
| 2022-06-30 |
1.82 |
$1.79 |
1.02 |
| 2022-03-31 |
1.50 |
$3.07 |
0.49 |
| 2021-12-31 |
2.96 |
$5.40 |
0.55 |
| 2021-09-30 |
10.32 |
$15.65 |
0.66 |
| 2021-06-30 |
11.65 |
$25.26 |
0.46 |
| 2021-03-31 |
18.10 |
$23.81 |
0.76 |
| 2020-12-31 |
17.00 |
$21.39 |
0.79 |
| 2020-09-30 |
22.00 |
$10.72 |
2.05 |
| 2020-06-30 |
27.40 |
0 |
0.00 |
| 2020-03-31 |
22.80 |
0 |
0.00 |
| 2019-12-31 |
45.60 |
$13.73 |
3.32 |
| 2019-09-30 |
16.90 |
$13.73 |
1.23 |
| 2019-06-30 |
19.52 |
$17.75 |
1.10 |
| 2019-03-31 |
25.20 |
$21.03 |
1.20 |
| 2018-12-31 |
64.80 |
$11.12 |
5.82 |
| 2018-09-30 |
48.20 |
$20.06 |
2.40 |
| 2018-06-30 |
55.80 |
$24.69 |
2.26 |
| 2018-03-31 |
95.00 |
$27.82 |
3.41 |
| 2017-12-31 |
116.60 |
$29.71 |
3.92 |
| 2017-09-30 |
42.00 |
$51.07 |
0.82 |
| 2017-06-30 |
93.60 |
$54.38 |
1.72 |
| 2017-03-31 |
156.40 |
$58.58 |
2.67 |
| 2016-12-31 |
245.20 |
$67.93 |
3.61 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.005B |
|
Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based in Seattle.
|
